Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

Novartis (NVS) recently hit a 52-week high, driven by strong earnings, with the latest EPS beating estimates by $0.16. The company's full-year EPS is projected to grow by 11.91% to $8.74 on $54.29 billion in revenue, supported by a Zacks Rank #2 (Buy) and favorable Style Scores, suggesting continued potential; Pfizer (PFE) is also noted as a strong industry peer.

Analysis

Novartis (NVS) has demonstrated significant stock appreciation, recently achieving a new 52-week high of $120.92, reflecting an 11.4% gain over the past month and a 24.1% increase year-to-date, substantially outperforming both the Zacks Medical sector's -1.5% decline and the Zacks Large Cap Pharmaceuticals industry's 2.8% return. This outperformance is underpinned by a consistent record of positive earnings surprises, with Novartis exceeding earnings consensus estimates for the last four consecutive quarters. In its most recent report on April 29, 2025, Novartis posted an EPS of $2.28, surpassing the $2.12 consensus, and beat revenue estimates by 2.88%. Projections for the current fiscal year indicate an EPS of $8.74, an 11.91% year-over-year increase, on revenues of $54.29 billion, a 7.13% rise. For the subsequent fiscal year, EPS is anticipated to reach $9.02, a 3.24% increase, with revenues of $55.2 billion, a 1.68% increase, indicating a moderation in growth. Despite its recent high, NVS trades at a current fiscal year P/E of 13.8X, slightly below the peer industry average of 14.1X, and a P/CF of 11.3X, which is in line with its peer group. The stock holds a Zacks Rank of #2 (Buy), supported by favorable earnings estimate revisions and a strong VGM Score of A, although its PEG ratio of 1.75 suggests it is not in the top tier from a pure value perspective. The Large Cap Pharmaceuticals industry, ranked in the top 16% by Zacks, provides a favorable operating environment, with Pfizer (PFE) also highlighted as a strong industry peer holding a Zacks Rank #2 (Buy) and presenting more attractive valuation multiples, such as a forward P/E of 8.11X and a P/CF of 5.69X.

Key Decisions for Investors

• Given Novartis's consistent earnings outperformance, positive analyst sentiment, and valuation metrics that are not excessively stretched despite its 52-week high, investors could consider maintaining existing positions or selectively adding, while remaining cognizant of the projected deceleration in growth for the next fiscal year.
• Investors should closely monitor upcoming earnings releases and revenue growth trends to ensure the company continues to meet or exceed expectations, particularly as the stock is trading near its peak and faces moderating growth forecasts.
• While NVS presents a solid investment case supported by a Buy rating and strong style scores, those seeking value within the favorably ranked Large Cap Pharmaceuticals sector might also assess industry peers like Pfizer, which offers a similar Buy rating but trades at lower valuation multiples.